Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Richard Dodel; Axel Rominger; Peter Bartenstein; Frederik Barkhof; Kaj Blennow; Stefan Förster; Yaroslav Winter; Jan-Philipp Bach; Julius Popp; Judith Alferink; Jens Wiltfang; Katharina Buerger; Markus Otto; Piero Antuono; Michael Jacoby; Ralph Richter; James Stevens; Isaac Melamed; Jerome Goldstein; Stefan Haag; Stefan Wietek; Martin Farlow; Frank Jessen

doi:10.1016/s1474-4422(13)70014-0

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

The Lancet Neurology ◽

10.1016/s1474-4422(13)70014-0 ◽

2013 ◽

Vol 12 (3) ◽

pp. 233-243 ◽

Cited By ~ 122

Author(s):

Richard Dodel ◽

Axel Rominger ◽

Peter Bartenstein ◽

Frederik Barkhof ◽

Kaj Blennow ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Intravenous Immunoglobulin ◽

Dose Finding ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

P4-411: A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10-04)

Alzheimer s & Dementia ◽

10.1016/j.jalz.2011.09.107 ◽

2011 ◽

Vol 7 ◽

pp. e55-e56 ◽

Cited By ~ 6

Author(s):

Richard Dodel ◽

Axel Rominger ◽

Kaj Blennow ◽

Frederik Barkhof ◽

Stefan Wietek ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Intravenous Immunoglobulin ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

P3-283: Randomized double-blind placebo-controlled dose-finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer's disease

Alzheimer s & Dementia ◽

10.1016/j.jalz.2010.05.1783 ◽

2010 ◽

Vol 6 ◽

pp. S534-S534

Author(s):

Martin R. Farlow ◽

Frank Jessen ◽

Stefan Wietek ◽

Tina Melsen ◽

Stefan Haag ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Intravenous Immunoglobulin ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3102957.2785055 ◽

2010 ◽

Author(s):

Jean-Francois Demonet

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Amyloid Beta ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Study

Download Full-text

The PIONEER Study: A multi‐center, randomized, double‐blind, placebo‐controlled phase 2 trial of the effects of T3D‐959 on safety, cognition, function and plasma biomarkers in mild to moderate Alzheimer’s disease subjects: Rationale and study design

Alzheimer s & Dementia ◽

10.1002/alz.039922 ◽

2020 ◽

Vol 16 (S9) ◽

Author(s):

John Didsbury ◽

Warren Strittmatter ◽

Stan Chamberlain ◽

Hoda Gabriel

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Study Design ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Plasma Biomarkers ◽

Phase 2 Trial ◽

Pioneer Study

Download Full-text

INVOKE‐2: A phase 2 randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of AL002 in participants with early Alzheimer’s disease

Alzheimer s & Dementia ◽

10.1002/alz.054615 ◽

2021 ◽

Vol 17 (S9) ◽

Author(s):

Robert Paul ◽

Sam Jackson ◽

Michael Ward ◽

Aashka Joshi ◽

Abraham Castro ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Controlled Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Early Alzheimer’S Disease

Download Full-text

P3-033: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS TREATMENT OF BIIB092 IN SUBJECTS WITH EARLY ALZHEIMER'S DISEASE: TANGO PHASE 2 STUDY DESIGN

Alzheimer s & Dementia ◽

10.1016/j.jalz.2018.06.1388 ◽

2006 ◽

Vol 14 (7S_Part_20) ◽

pp. P1077-P1077 ◽

Cited By ~ 1

Author(s):

Elena Ratti ◽

Bjoern Sperling ◽

Tina Olsson ◽

Li Zhang ◽

Kumar Kandadi Muralidharan ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Study Design ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Early Alzheimer’S Disease

Download Full-text

P2-006: Exploratory Analyses of Cognitive Effects of Crenezumab in a Mild Alzheimer's Disease Subpopulation of a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Study (ABBY)

Alzheimer s & Dementia ◽

10.1016/j.jalz.2016.06.1210 ◽

2016 ◽

Vol 12 ◽

pp. P610-P610 ◽

Cited By ~ 2

Author(s):

Howard Mackey ◽

William Cho ◽

Michael Ward ◽

Yuan Fang ◽

Shehnaaz Suliman ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cognitive Effects ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group ◽

Phase 2 Study

Download Full-text

O4-11-06: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

Alzheimer s & Dementia ◽

10.1016/j.jalz.2014.04.450 ◽

2014 ◽

Vol 10 ◽

pp. P275-P275 ◽

Cited By ~ 14

Author(s):

Jeffrey Cummings ◽

William Cho ◽

Michael Ward ◽

Michel Friesenhahn ◽

Flavia Brunstein ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

The Lancet Neurology ◽

10.1016/s1474-4422(10)70043-0 ◽

2010 ◽

Vol 9 (4) ◽

pp. 363-372 ◽

Cited By ~ 464

Author(s):

Juha O Rinne ◽

David J Brooks ◽

Martin N Rossor ◽

Nick C Fox ◽

Roger Bullock ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Amyloid Β ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Study

Download Full-text

Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(14)70198-x ◽

2014 ◽

Vol 13 (11) ◽

pp. 1092-1099 ◽

Cited By ~ 100

Author(s):

David Wilkinson ◽

Kristian Windfeld ◽

Eskild Colding-Jørgensen

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Receptor Antagonist ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial

Download Full-text